teclistamab,daratumumab,talquetamab
genmab,janssen
['nct04586426', 'redirectt-1', 'janssen']
results from the redirectt-1 trial (nct04586426) presented by at the 2023 demonstrated significant response rates across various dosage levels. explore more at: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry